Drugs / Methionine

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03887169 Sep 2019 → Jun 2020 inborn mitochondrial metabolism disorder, pulmonary alveolar proteinosis Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00840047 Jul 2009 → Jul 2027 expected Ewing sarcoma, Hodgkins lymphoma, brain stem glioma, craniopharyngioma +6 St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02824419 May 2016 → May 2017 pulmonary sarcoidosis Turku University Hospital Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT00032695 AIDS-related disorder, spinal cord disorder National Institute of Neurological Disorders and Stroke (NINDS) Completed No outcome recorded
Phase not applicable3 trials
NCT00253773 Jan 2005 → Nov 2007 disorder of defective peroxisome oxidative status National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Completed No outcome recorded
NCT00253760 Feb 2004 → Feb 2007 diabetes mellitus, heart disorder National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Completed No outcome recorded
NCT00597246 May 2003 → Nov 2019 brain cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as methionine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00253760
6

NCT00032695

NCT00597246

NCT02824419

NCT00253773

NCT03887169

NCT00840047

Known as MET Methionine (MET)” NCT00840047
Action Restore restores MetRS function” NCT03887169
Modality Other / unclassified “dietary amino acids; cysteine and methionine” NCT00253760
Route Intravenous “i.v. administration of \[11C-methyl\]-L-methionine” NCT00597246